Released Aug 8, 2024, before the open
10-Q filed Aug 8, 2024, 39 days after period end · 0001785530-24-000028
Q2 2024 · 10-Q
Revenue—
Net Income-$17.25M-$17.25M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.43-$0.43 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$18,960,000N/M
Operating Cash Flowderived-$14,177,000N/M
Free Cash Flowderived-$14,194,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$17.25M | -$5.10M | -$14.59M | -$10.92M |
| EPS Diluted | -$0.43 | -$0.14 | -$0.53 | -$3.82 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR